Department of Respiratory Medicine, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka, 591-8555, Japan.
Department of Radiology, NHO Kinki Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai City, Osaka, 591-8555, Japan.
Respir Investig. 2024 Sep;62(5):872-878. doi: 10.1016/j.resinv.2024.07.015. Epub 2024 Jul 30.
Anti-synthetase syndrome-associated interstitial lung disease (ASS-ILD) may occur without myositis. Although a recent Japanese guide proposed a watch-and-wait approach for chronic ASS-ILD without obvious progression, the natural history of this subgroup and the appropriateness of the watch-and-wait approach remain unclear. We aimed to describe the natural history of ASS-ILD, that is sufficiently indolent to be a candidate for the watch-and-wait approach.
Among consecutive patients with ASS-ILD, we retrospectively identified those without myositis, acute/subacute onset, and significant lung function impairment, which qualified them as indolent-ASS-ILD cases, and described their natural course. Additionally, we evaluated the risk factors for fibrosis progression on computed tomography (CT) using the Cox proportional hazards model.
Among 80 patients with ASS-ILD, we identified 33 with indolent-ASS-ILD, all of whom were initially followed up with a watch-and-wait approach. Among 30 patients with sufficient follow-up data, 27 (90%) showed a stable course without treatment over 24 months. Subsequently, four patients experienced ≥10% relative forced vital capacity (FVC) decline without treatment during a median follow-up duration of 81 months. Seven patients showed fibrosis progression with >10% increase in the total lung area on CT. Higher levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) were associated with fibrosis progression on CT.
Most patients with indolent-ASS-ILD did not experience ≥10% relative FVC decline over five years without treatment. However, fibrosis progression on CT, which seemed to precede significant FVC decline, occurred more frequently, especially in patients with higher KL-6 and SP-D levels.
抗合成酶综合征相关间质性肺病(ASS-ILD)可在无肌炎的情况下发生。尽管最近的一份日本指南提出了一种对无明显进展的慢性 ASS-ILD 进行观察等待的方法,但该亚组的自然病程和观察等待方法的适宜性仍不清楚。我们旨在描述 ASS-ILD 的自然病程,即其惰性足以成为观察等待方法的候选者。
在连续的 ASS-ILD 患者中,我们回顾性地确定了那些无肌炎、急性/亚急性起病和明显的肺功能损害的患者,这些患者符合惰性 ASS-ILD 病例的标准,并描述了他们的自然病程。此外,我们使用 Cox 比例风险模型评估 CT 上纤维化进展的风险因素。
在 80 例 ASS-ILD 患者中,我们确定了 33 例惰性 ASS-ILD 患者,所有患者最初均采用观察等待方法进行随访。在 30 例具有足够随访数据的患者中,27 例(90%)在 24 个月的无治疗随访期间表现出稳定的病程。随后,在中位随访 81 个月期间,有 4 例患者在无治疗的情况下经历了≥10%的相对用力肺活量(FVC)下降。7 例患者的 CT 上总肺面积增加了>10%,显示出纤维化进展。较高的 KL-6 和表面活性蛋白-D(SP-D)水平与 CT 上的纤维化进展相关。
大多数惰性 ASS-ILD 患者在五年内不接受治疗时,FVC 相对下降不会超过 10%。然而,CT 上的纤维化进展(似乎先于显著的 FVC 下降)更频繁发生,尤其是在 KL-6 和 SP-D 水平较高的患者中。